Intismeran autogene
Merck & Co. · Moderna · V940 · mRNA-4157
FollowEvery change as it happens, and a Monday email
Trials
11 active
12 in total · 10 in the EU
What this is
- How it works
- Personalised mRNA cancer vaccine
- How it’s given
- “Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.”In the company’s words, NCT06305767 on ClinicalTrials.gov
- Tested for
- Melanoma (2 trials), Non-small Cell Lung Cancer (2 trials), Carcinoma, Non-Small-Cell Lung, Renal Cell Carcinoma, Malignant Melanoma, Squamous Non-small Cell Lung Cancer, Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms and 3 more
- Main trialPhase 3
- “The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.”In the company’s words, NCT05933577 on ClinicalTrials.gov
- Other names
- V940 · mRNA-4157 · Intismeran
Other drugs for Melanoma
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up11
- 23 Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 21 Nov 2027Phase 1 trial completes · ClinicalTrials.gov
- 8 Jan 2028Phase 2 trial completes · ClinicalTrials.gov
- 22 Jul 2028Phase 2 trial completes · ClinicalTrials.gov
- 2 Jul 2029Phase 2 trial completes · ClinicalTrials.gov
- 26 Oct 2029Phase 3 trial completes · ClinicalTrials.gov
- 25 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
- 3 Sep 2031Phase 2 trial completes · ClinicalTrials.gov
- 21 Nov 2032Phase 2 trial completes · ClinicalTrials.gov
- 16 May 2033Phase 3 trial completes · ClinicalTrials.gov
- 22 Aug 2034Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT06961006
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 26 Oct 2029 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | |
| Phase 3Active, not recruiting | 25 Jun 2030 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | |
| Phase 3Recruiting | 16 May 2033 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | |
| Phase 3Recruiting | 22 Aug 2034 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) | |
| Phase 2Active, not recruiting | 8 Jan 2028 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | |
| Phase 2Active, not recruiting | 22 Jul 2028 | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | |
| Phase 2Recruiting | 2 Jul 2029 | A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | |
| Phase 2Recruiting | 3 Sep 2031 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | |
| Phase 2Active, not recruiting | 21 Nov 2032 | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | |
| Phase 1/2Active, not recruiting | 23 Apr 2027 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | |
| Phase 1Active, not recruiting | 21 Nov 2027 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors | |
| Phase 2/3Terminated | 5 Mar 2026 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026